Chemical formula: C₁₇H₁₂F₃NO₄S Molecular mass: 383.044 g/mol PubChem compound: 117947097
Belzutifan is indicated for:
Population group: only adults (18 - 65 years old)
Belzutifan is indicated for treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only adults (18 - 65 years old)
Belzutifan is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI).
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Belzutifan is contraindicated in the following cases:
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
